US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Carbiotix provides Q4 2024 update of ongoing NutraCycle projects

Carbiotix AB (publ) ("Carbiotix" or the "Company") announces today the Q4 2024 update regarding its ongoing NutraCycle projects. Since September 30th, the total number of customer projects doubled to 32 in total. Carbiotix added 16 new customer projects and its first customer projects in Asia. Customer projects now include 4 customers which each have annual revenues exceeding 10 billion USD. The Company added 21 new customer side-streams and now has customer projects across 40 side-streams in total.Erik Deaner, CEO of Carbiotix, comments:The increasing number of customer projects that we

Carbiotix provides Q3 2024 update of ongoing NutraCycle projects

Carbiotix AB (publ) ("Carbiotix" or “the Company") announces today an update for Q3 2024 regarding its ongoing NutraCycle projects as previously communicated. Since August 29th, the total number of customer projects increased by four, bringing the total to sixteen. The Company has added three laboratory pre-studies and one pilot pre-study. Carbiotix expanded its customer base with three new customer projects in Europe and its first customer project in Africa. Among these new customers are two companies with annual revenues exceeding 1 billion USD. Additionally, five new customer side-streams

Carbiotix initiates eight new NutraCycle pre-study projects and will begin quarterly reporting of new and ongoing customer projects

Carbiotix AB (publ) ("Carbiotix" or the "Company") announces today that the Company has initiated eight new NutraCycle pre-study projects and will begin quarterly reporting of both new and ongoing customer projects. The eight new projects are in addition to the two ongoing pre study projects and one joint development project previously communicated. This brings the total number of customer projects to eleven, with twelve different and side-stream products being examined. The Company attributes this rapid growth of NutraCycle projects to its recent participation at VitaFoods Europe in May and

Carbiotix completes metformin study and provides EU funding update

Carbiotix (publ) ("Carbiotix" or the "Company") announces today that the metformin study has now been completed after aligning with the project group. While the Polymerase Chain Reaction (PCR) results communicated on November 1st, 2023, indicated that 20% of patients in the intervention cohort responded positively to a prebiotic containing CarbiAXOS, experiencing an average improvement of 15% in HbA1c (blood glucose) levels and an upregulation of Short Chain Fatty Acid (SCFA) levels, the Next Generation Sequencing (NGS) results after bioinformatic analysis were inconclusive due to the study’s

The Board of Directors of Carbiotix AB (publ) proposes a directed share issue of a maximum of approximately SEK 7.00 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE, JAPAN, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD NOT BE IN COMPLIANCE WITH APPLICABLE LAWS OR REGULATIONS OR WOULD REQUIRE REGISTRATION OR SIMILAR MEASURES. The Board of Directors of Carbiotix AB (publ) (“Carbiotix” or the “Company”) has today resolved to propose a directed share issue of a maximum of 175,000,024 shares at a

Carbiotix AB’s warrant exercise registered at the Swedish Companies Registration Office

Carbiotix AB ("Carbiotix" or "Company") today announces that the new shares from the exercise of warrants of series TO 3 have been registered with the Swedish Companies Registration Office.On 19 June 2024, the exercise period for warrants of series TO 3, which were issued in connection with Carbiotix’s rights issue of units earlier in 2024, ended. As a result of the warrant exercise, 20,796,181 new shares have now been registered with the Swedish Companies Registration Office. The total number of shares in the Company after the exercise of warrants of series TO 3 amounts to 201,022,976 and

Carbiotix AB announces the outcome of the exercise of warrants of series TO 3

On June 19, 2024, the exercise period for Carbiotix AB's ("Carbiotix" or "Company") warrants of series TO 3 ("TO 3") ended. In total, 20,796,181 warrants of series TO 3 have been exercised, corresponding to approximately 39 percent of the total number of warrants, which means that the Company receives approximately SEK 0.83 million before deductions for issue costs.During the period 5-19 June 2024, holders of warrants of series TO 3 have had the right to subscribe for shares with the support of warrants. One (1) warrant of series TO 3 gave the holder the right to subscribe for one (1) new

Carbiotix provides update of staff re-organisation

Carbiotix AB (publ) ("Carbiotix" or the "Company") has today provided an update of the staff re-organisation originally communicated on May 28th. Five individuals will be impacted by the re-organisation, including three full-time employees and two consultants. Included among these individuals are CIO Martin Erlandsson and CMO Richard Rosenbloom, who will thereby leave the management team of Carbiotix. At the same time, and as previously communicated, Carbiotix will be expanding its process engineering team to meet an increased demand for its NutraCycle service.Erik Deaner, CEO of Carbiotix,

The last day of trading in warrants of series TO 3 is on the 17th of June 2024

The 17th of June 2024 is the last day of trading in warrants of series TO 3, which were issued in connection with Carbiotix AB's ("Carbiotix" or the "Company") preferential rights issue of units that was carried out in January 2024. The exercise period runs until the 19th of June 2024.In connection with the Company's preferential rights issue of units carried out in January 2024, 53,163,522 warrants of series TO 3 were issued. Holders of TO 3 have the right to subscribe for one (1) new share in Carbiotix at a price of SEK 0.04 per share during the exercise period, which runs until June 19th,

The exercise period for warrants of series TO 3 commences today

Today is the first day for the exercise of Carbiotix AB's ("Carbiotix" or "Company") warrants of series TO 3 ("TO 3") which were issued in connection with the preferential issue of units the Company carried out earlier this year. The period lasts until June 19, 2024. Holders of TO 3 have the right to subscribe for one (1) new share in Carbiotix for each TO 3 at a price of SEK 0.04 per share. Through full use of TO 3, the Company can receive a maximum of approximately SEK 2.1 million before issue costs. An information document is available on the respective websites of Carbiotix (www.carbiotix.

The exercise price for warrants of series TO 3 has been set to SEK 0.04 per new share

Carbiotix AB ("Carbiotix" or "the Company") hereby announces that the exercise price for the warrants of series TO 3 (”TO 3”), which were issued in connection with the rights issue of units the Company executed earlier during 2024, has been set. The exercise price for TO 3 has been set to SEK 0.04 per share and the exercise period commences on June 5th, 2024.In January 2024, Carbiotix carried out a rights issue which brought the Company approximately SEK 11.2 million before issue costs. Through the rights issue, 53,163,522 warrants of series TO 3 were issued. Each TO 3 entitles the holder

Carbiotix announces strategic re-focus and staff re-organisation

Carbiotix (publ) ("Carbiotix" or the "Company") announces today that the company will implement a strategic re-focus after positive feedback from the VitaFoods tradeshow in Geneva. As a consequence, the Company will re-organise its staff. This re-organisation reflects a decision by the Board of Directors to focus on the growth of its NutraCycle service in the near to medium term. The people who will be affected by the re-organisation will be confirmed after contact is made with the appropriate union representatives. Carbiotix will also be expanding its process engineering team to meet an

Carbiotix signs first NutraCycle Joint Development Agreement with leading Nordic plant-based food & beverage producer

Carbiotix (publ) ("Carbiotix" or the "Company") announces today that the Company has signed its first NutraCycle Joint Development Agreement (JDA) with a leading Nordic plant-based food & beverage producer. The JDA follows a successful Pre-Study consisting of both laboratory and pilot scale verification of a new Carbersol process and prebiotic. The Joint Development phase will include process development, process engineering and product formulation work and will be carried within the next 6 months with the goal of making a decision on building a Carbersol process.NutraCycle is a distributed

Carbiotix commences NutraCycle pilot study with leading US food & beverage producer

Carbiotix (publ) ("Carbiotix" or the "Company") announces today that the Company has commenced a pilot study with the same leading US food & beverage producer mentioned in a March 6th press release. The pilot study is the second step in the NutraCycle Pre-Study and commences only after a successful laboratory study. In this case, the laboratory study verified both a viable process and upcycled Carbersol prebiotic ingredient that also has the potential to replace sugars, texturizers and provide other health benefits. The pilot study will validate the process and Carbersol prebiotic ingredient

Carbiotix rebrands prebiotic ingredient CarbiAXOS to Carbersol

Carbiotix (publ) ("Carbiotix" or the "Company") announces today that the Company has decided to rebrand its prebiotic ingredient CarbiAXOS to Carbersol. This rebranding decision aims to better reflect current and future prebiotic products that Carbiotix will focus on, in addition to accelerating time to market for different prebiotic products. Carbiotix will update its website in the coming days to reflect this change as well as other recent news.Erik Deaner, CEO of Carbiotix, comments:“The decision to rebrand our prebiotic ingredient CarbiAXOS to Carbersol at this time is very logical.

Carbiotix announces European and US tradeshow schedule for 2024

Carbiotix (publ) ("Carbiotix" or the "Company") announces today the Company’s 2024 tradeshow schedule for Europe and US. Carbiotix will participate and exhibit at three leading tradeshows focusing on food, nutraceutical and cosmetic ingredients. This initiative follows the recent GRAS approval of CarbiAXOS, the IVDR status of LinkGut, and the launch of the NutraCycle upcycling service. Following these milestones, Carbiotix is now ramping up marketing and sales activities in Europe and the US to promote the Company’s unique value proposition.Erik Deaner, CEO of Carbiotix, comments:“I am

Carbiotix ramps up prebiotic and technology partner evaluation activities

Carbiotix (publ) ("Carbiotix" or the "Company") announces today that the Company has increased evaluation activities for prebiotics and technology partners. These activities coincide with the recent hiring of Calle Sjöström as Chief Process Engineer (CPE) and Hannah Linander as microbiologist, the market introduction of CarbiAXOS, and the launch of the NutraCycle service. Carbiotix will continue to evaluate new and existing prebiotics for how they fit and complement CarbiAXOS. Furthermore, Carbiotix will also explore production techniques to improve the manufacturing of prebiotic products.

Carbiotix receives first animal related LinkGut service order

Carbiotix (publ) ("Carbiotix" or the "Company") announces today that the Company’s first ever animal-related LinkGut service order from a leading company developing microbiome intervention solutions for different human and animal applications. This test order relates to samples taken from canines and is valued at 32,000 SEK. This is the first time that Carbiotix has offered its LinkGut microbiome diagnostic service for animal related applications. This development increases the potential customer base for the LinkGut service, now including both human and animal applications.Erik Deaner, CEO

Carbiotix commences NutraCycle pre-study with leading US food & beverage producer

Carbiotix (publ) ("Carbiotix" or the "Company") announces today that the Company has commenced a pre-study with a leading US food & beverage producer with a turnover exceeding 2 billion USD. This NutraCycle pre-study is the first step when working with food & beverage companies to determine if a side-stream product can be upcycled into a prebiotic that can be primarily utilized in the fortification of new and existing products. The pre-study is typically completed within a 3-month period and includes initial lab and pilot scale product & process development work and microbial validation.

Carbiotix launches NutraCycle – a new upcycling service for food & beverage producers

Carbiotix (publ) ("Carbiotix" or the "Company") announces today that the Company has launched a new upcycling service for food & beverage producers, named NutraCycle. This new service leverages key process and product knowledge gained from the development of novel prebiotics such as CarbiAXOS that is derived from various food & beverage side stream products. It opens the door for Carbiotix to get exposure and generate value from the largest segment of the prebiotics industry; food and beverage applications. Carbiotix will immediately ramp up both marketing and sales activities targeting both

Carbiotix receives a LinkGut clinical study order for 1 MSEK

Carbiotix (publ) ("Carbiotix" or the "Company") announces today that the Company has received a LinkGut clinical study order for 1 MSEK from a leading microbiome science and consumer products company. This order represents Carbiotix first LinkGut clinical study order after recently achieving IVDR status for its LinkGut test kit. Payment for the order will be made in 2024 starting in Q1 when kits are sent out and ongoing as they are sent back and analyzed. Carbiotix will continue to ramp up commercial activities regarding its LinkGut service to microbiome science companies, Contract Research

Carbiotix achieves IVDR and CE marked status for LinkGut testing kit

Carbiotix (publ) ("Carbiotix" or the "Company") announces today that the Company has received IVDR (In Vitro Diagnostic Regulation) Class A and CE marked status for its LinkGut microbiome testing kit. This represents a key milestone in the development of the testing kit, fulfilling the requirements of several existing and potential customers, and opens up the LinkGut service to the much larger and faster growing clinical study and research segment of the microbiome sequencing services market.Erik Deaner, CEO of Carbiotix, comments:“I am extremely pleased to announce that our LinkGut

Carbiotix AB announces last day of trading in BTU and first day of trading in TO 3

Carbiotix AB's ("Carbiotix" or the "Company") preferential issue of units, with a subscription period ending on January 31, 2024, has now been registered at the Swedish Companies Registration Office. The Company hereby announces that the last day of trading in BTU (paid subscribed unit) is 20 February 2024, and the stop day is 22 February 2024. The first day of trading in warrants of series TO 3 is 26 February 2024.In January 2024, Carbiotix carried out a rights issue which provided the Company with approximately SEK 14.2 million before issue costs. The rights issue has now been registered

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media